U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula Ra
Molecular Weight 223.0185
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 2

SHOW SMILES / InChI
Structure of RADIUM RA-223 CATION

SMILES

[Ra+2]

InChI

InChIKey=PZDJSXWIQXZUBJ-OIOBTWANSA-N
InChI=1S/Ra/q+2/i1-3

HIDE SMILES / InChI

Description
Curator's Comment:: description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/?term=23653243; http://www.ncbi.nlm.nih.gov/pubmed/?term=23977665

Radium Ra 223 dichloride is a radiotherapeutic drug that is approved for the treatment of male patients with symptoms of advanced prostate cancer with bone metastases. Ra 223 mimics calcium and forms complexes with the bone mineral hydroxyapatite at areas of increased bone turnover. The radioactive alpha particles emitted by radium Ra 223 helps in killing cancer cells in the bone by damaging their DNA. Radium Ra 223 causes minimal damage to the nearby healthy cells.

Originator

Curator's Comment:: Xofigo (RADIUM RA-223 DICHLORIDE) was discovered by Algeta ASA, a Norwegian biotech, and in-licensed by Bayer

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
XOFIGO

Approved Use

Xofigo is an alpha particle-emitting radioactive thera peutic agent indicated for the treatment of patients with castration-resistant prostate cancer, symptoma tic bone metastases and no known visceral metastatic disease

Launch Date

1.36857597E12
PubMed

PubMed

TitleDatePubMed
L-dihydroxyphenylserine (Droxidopa) in the treatment of orthostatic hypotension: the European experience.
2008 Mar
A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer.
2013 Feb
Phase I pharmacokinetic and biodistribution study with escalating doses of ²²³Ra-dichloride in men with castration-resistant metastatic prostate cancer.
2013 Sep
Patents

Sample Use Guides

The dose regimen is 50 kBq (1.35 microcurie) per kg body weight, given at 4 week intervals for 6 injections.
Route of Administration: Intravenous
Radium-223 dichloride showed a dose-dependent inhibition of MDA-MB-231(SA) breast cancer cell proliferation at concentrations of 400, 800 and 1600 Bq/mLcompared to the control in a 5-day in vitro proliferation assay
Name Type Language
RADIUM RA-223 CATION
Common Name English
RADIUM, ISOTOPE OF MASS 223 (223RA2+)
Common Name English
RADIUM-223 ION(2+)
Common Name English
Classification Tree Code System Code
NDF-RT N0000187053
Created by admin on Sat Jun 26 05:17:44 UTC 2021 , Edited by admin on Sat Jun 26 05:17:44 UTC 2021
Code System Code Type Description
DRUG BANK
DB14571
Created by admin on Sat Jun 26 05:17:44 UTC 2021 , Edited by admin on Sat Jun 26 05:17:44 UTC 2021
PRIMARY
RXCUI
1745075
Created by admin on Sat Jun 26 05:17:44 UTC 2021 , Edited by admin on Sat Jun 26 05:17:44 UTC 2021
PRIMARY
FDA UNII
9H414A99MD
Created by admin on Sat Jun 26 05:17:44 UTC 2021 , Edited by admin on Sat Jun 26 05:17:44 UTC 2021
PRIMARY
NDF-RT
N0000187052
Created by admin on Sat Jun 26 05:17:44 UTC 2021 , Edited by admin on Sat Jun 26 05:17:44 UTC 2021
PRIMARY alpha-Particle Emitting Activity [MoA]